Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 11/20 | 0.56 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.56 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.54 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.44 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.44 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756233 | 0.84 | ESR1 (0.68) | ESR1ESR2EBPSIGMAR1CYP1A2 | |
| SCHEMBL11880808 | 0.78 | ESR1 (0.72) | ESR1ESR2EBPSIGMAR1MAPT | |
| SCHEMBL14982030 | 0.78 | ESR1 (0.59) | ESR1ESR2EBPSIGMAR1ACHE | |
| SCHEMBL13109358 | 0.77 | EBP (0.74) | ESR1ESR2EBPSIGMAR1PTPN1 | |
| Hydrochloric Acid SCHEMBL2904005 | 0.75 | ESR1 (0.48) | ESR1ESR2EBPSIGMAR1ACHE | |
| SCHEMBL4419991 | 0.74 | ESR1 (0.53) | ESR1ESR2EBPSIGMAR1CYP1A2 | |
| Nafoxidine SCHEMBL7259634 | 0.74 | EBP (0.70) | ESR1ESR2EBPSIGMAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL31070043 | 0.74 | MAPT (0.66) | EBPSIGMAR1HTTBCHEACHE | |
| Hydrochloric Acid SCHEMBL11835786 | 0.74 | MAPT (0.66) | EBPSIGMAR1HTTBCHEACHE | |
| SCHEMBL9993383 | 0.73 | EBP (0.74) | ESR1ESR2EBPSIGMAR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310385-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| CN-108348605-B | Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens | 帕拉卡林治疗公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| WO-2023275715-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20200030259-A1 | Antiestrogens and/or Aromatase Inhibitors for Use in Treating Obesity and Related Symptoms | REPROS THERAPEUTICS INC (US) | 2020-01-30 | — | — | US | disclosed |
| EP-2819676-B1 | COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY | REPROS THERAPEUTICS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9687458-B2 | Trans-clomiphene for use in cancer therapy | REPROS THERAPEUTICS INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-8372887-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120022167-A1 | Trans-Clomiphene for Metabolic Syndrome | REPROS THERAPEUTICS INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-7737185-B2 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090099265-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| US-20070249726-A1 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |